

Consolidated Financial Results for the Nine Months Ended September 30, 2025 [Japanese GAAP]

November 14, 2025 Listing: Tokyo Stock Exchange

Company name: Medical Data Vision Co., Ltd. Securities code:

Representative:

3902 URL https://www.mdv.co.jp/

(Title) President (Name) Hiroyuki Iwasaki

(Title) Executive Officer and General Manager of (Name) Kenji Ogura Tel: +81-3-5283-6911 Inquiries:

Corporate Planning Division

Scheduled date to commence dividend payments:

Preparation of supplementary material on quarterly financial results: Yes

: Yes (for institutional investors and analysts) Holding of quarterly financial results briefing

(Yen amounts are rounded down to millions, unless otherwise noted)

1. Consolidated financial results for the Nine months ended September 30, 2025 (from January 1, 2025 to September 30, 2025)

(1) Consolidated operating results (cumulative)

(1) Collsolidated operating to	esuns (cumura	ilive)			(1	ercentages inc	ncate year-on-	year changes)
	Net s	sales	Operating income		Ordinary income		Net income attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Nine months ended	4.650	12.7	0.5		106		5.5	
September 30, 2025 Nine months ended	4,650	12.7	95	-	106	-	55	-
September 30, 2024	4,125	-8.1	-140	-	-229	-	-314	-

Nine months ended September 30, 2025 62 million yen [-%] (Note) Comprehensive income Nine months ended September 30, 2024 -280 million yen [-%]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Nine months ended		
September 30, 2025	1.46	-
Nine months ended		
September 30, 2024	-8.24	-

- Diluted earnings per share for the third quarter of the fiscal year ended December 31, 2024 is not shown because it is a quarterly net loss, although there are potential shares
 - 2. Diluted earnings per share for the third quarter of the fiscal year ending December 31, 2025 are not presented as there are no potentially dilutive shares.

(2) Consolidated financial position

(2) Combondated infancial	position		
	Total assets	Net assets	Equity-to-asset ratio
	Millions of yen	Millions of yen	%
As of September 30, 2025	4,586	2,897	62.4
As of December 31, 2024	4,749	3,154	65.1

(Reference) Equity As of September 30, 2025 2,861 million yen As of December 31, 2024 3,093 million yen

2. Cash dividends

2. Cash dividends						
	Annual dividends per share					
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total	
	Yen	Yen	Yen	Yen	Yen	
FY ended						
December 31, 2024	-	0.00	-	6.50	6.50	
FY ending						
December 31, 2025	-	0.00	-			
FY ending						
December 31, 2025						
(forecast)				9.00	9.00	

(Note) Revision of the latest released dividend forecast : None

3. Consolidated earnings forecasts for the fiscal year ending December 31, 2025 (from January 1, 2025 to December 31, 2025)

(Percentages indicate year-on-year changes)

	Net sa	les	Operating	income	Ordinary	income	Net income a to owners of	0	Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	6,860	16.1	490	-	500	-	270	-	7.13

(Notes) Revision of the latest released earnings forecasts: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies (Company name) , Excluded: - companies (Company name)

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements : None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations : Yes

(ii) Changes in accounting policies other than (i) above: None
(iii) Changes in accounting estimates: None
(iv) Restatement: None

(Notes) For more details, please refer to "(3) Notes to quarterly consolidated financial statements (Notes on change in accounting policies)

in 2. Quarterly consolidated financial statements and Key notes" on page 4 of the attached materials.

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

(ii) Number of treasury shares at the end of the period

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

As of September 30, 2025	40,027,526 shares	As of September 30, 2024	40,027,526 shares
As of September 30, 2025	2,170,748 shares	As of September 30, 2024	2,170,748 shares
Nine months ended September 30, 2025		Nine months ended September 30, 2024	38,196,829 shares

^{*} Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

The forward-looking statements, including earnings forecasts, contained in this material are based on information currently available to the Group and on certain assumptions deemed to be reasonable.

^{*} Proper use of earnings forecasts, and other special matters

2. Quarterly consolidated financial statements and key notes (1) Quarterly consolidated balance sheet

	(Thousands of yen)		
	As of December 31, 2024	As of September 30, 2025	
Assets			
Current assets			
Cash and deposits	1, 347, 266	1, 707, 94	
Accounts receivable – trade and contract assets	1, 038, 579	877, 14	
Raw materials	9, 844	25, 15	
Other	729, 520	508, 03	
Allowance for doubtful accounts	-13, 739	-12, 28	
Total current assets	3, 111, 471	3, 105, 99	
Non-current assets			
Property, plant and equipment	238, 132	200, 52	
Intangible assets			
Software	417	20	
Goodwill	64, 213	44, 94	
Total intangible assets	64, 630	45, 1	
Investments and other assets			
Investment securities	438, 348	455, 0	
Other	1, 034, 944	909, 79	
Allowance for doubtful accounts	-138, 420	-129, 6	
Total investments and other assets	1, 334, 872	1, 235, 23	
Total non-current assets	1, 637, 636	1, 480, 8	
Total assets	4, 749, 108	4, 586, 8	
iabilities			
Current liabilities			
Accounts payable - trade	218, 749	224, 6	
Income taxes payable	13, 946	14, 3	
Contract liabilities	807, 194	1,004,2	
Provision for bonuses	185	31, 7	
Other	398, 490	257, 7	
Total current liabilities	1, 438, 566	1, 532, 70	
Non-current liabilities			
Asset retirement obligations	142, 770	143, 24	
Other	13, 230	13, 3	
Total non-current liabilities	156, 000	156, 6	
Total liabilities	1, 594, 566	1, 689, 30	
Vet assets	, ,		
Shareholders' equity			
Share capital	992, 661	992, 6	
Capital surplus	1, 838, 540	1, 786, 6	
Retained earnings	2, 756, 070	2, 565, 3	
Treasury shares	-2, 494, 545	-2, 494, 5	
Total shareholders' equity	3, 092, 726	2, 850, 0	
Accumulated other comprehensive income	o, 00 2 , 1 2 0	2, 550, 5	
Valuation difference on available-for-sale securities	390	11,8	
Total accumulated other comprehensive income	390	11,8	
Share acquisition rights	7, 920	7, 8	
Non-controlling interests	53, 503	27,7	
Total net assets	3, 154, 541	2, 897, 5	
Total liabilities and net assets	4, 749, 108	4, 586, 89	

(2) Quarterly consolidated statement of income and quarterly consolidated statement of comprehensive income (Quarterly consolidated statement of income)

(Nine-month period)

	(T	housands of yen)
	Nine months ended September 30, 2024	Nine months ended September 30, 2025
Net sales	4, 125, 900	4, 650, 192
Cost of sales	1, 070, 796	1, 402, 094
Gross income	3, 055, 103	3, 248, 097
Selling, general and administrative expenses	3, 195, 627	3, 152, 157
Operating income(loss)	-140, 524	95, 939
Non-operating income		
Interest income	282	2, 516
Dividend income	563	562
Subsidy income	-	7, 190
Reversal of allowance for doubtful accounts	513	3, 456
Other	811	4,770
Total non-operating income	2, 170	18, 496
Non-operating expenses		
Provision of allowance for doubtful accounts	-	1, 24
Share of loss of entities accounted for using equity Method	91, 470	5, 358
Other	-	1, 100
Total non-operating expenses	91, 470	7, 700
Ordinary income(loss)	-229, 823	106, 73
Extraordinary income		
Gain on reversal of share acquisition rights	47	45
Total extraordinary income	47	45
Extraordinary losses		
Loss on retirement of non-current assets	90	1, 188
Loss on valuation of investment securities	127, 174	-
Total extraordinary losses	127, 265	1, 188
Net income (loss) before income taxes	-357, 041	105, 59
Income taxes – current	19, 492	39, 160
Income taxes – deferred	-58, 808	15, 424
Total income taxes	-39, 316	54, 58
Net income(loss)	-317, 725	51, 00'
Net loss attributable to non-controlling interests	-2, 890	-4, 31
Net income(loss) attributable to owners of parent	-314, 834	55, 324

(Quarterly consolidated statement of comprehensive income) (Nine-month period)

	(Th	nousands of yen)
	Nine months ended September 30, 2024	Nine months ended September 30, 2025
Net income(loss)	-317, 725	51,007
Other comprehensive income		
Valuation difference on available-for-sale securities	37, 323	11, 422
Total other comprehensive income	37, 323	11, 422
Comprehensive income	-280, 401	62, 429
Comprehensive income attributable to:		
Owners of parent	-277, 511	66, 747
Non-controlling interests	-2, 890	-4, 317

(3) Notes to quarterly consolidated financial statements

(Notes on going concern assumption)

Not applicable

(Notes to substantial changes in the amount of shareholders' equity)

Not applicable

(Notes on quarterly consolidated statements of cash flows)

Consolidated statement of Cash Flows for nine months ended of September 30, 2025 has not been made. Depreciation and amortization (including amortization related to intangible assets excluding goodwill) and amortization of goodwill for the third quarter of fiscal year 2025 are as follows.

	Nine months ended September 30, 2024	Nine months ended September 30, 2025
Depreciation	50,910 thousands of yen	61,762 thousands of yen
Amortization of goodwill	19,263 thousands of yen	19,263 thousands of yen

(Notes on segment information, etc.)

Segment information

Segment information is omitted as the Group is comprised of a single segment of the medical data network business.

(Notes on change in accounting policies)

(Application of "Accounting Standard for Current Income Taxes", etc.)

"Accounting Standard for Current Income Taxes" (ASBJ Statement No. 27, October 28, 2022; hereinafter referred to as the "Revised Accounting Standard 2022"), etc. have been adopted from the beginning of the first quarter consolidated fiscal year under review.

The amendment to categories in which current income taxes should be recorded (taxes on other comprehensive income) follows the transitional treatment prescribed in the proviso of paragraph 20-3 of the Revised Accounting Standard 2022 and the transitional treatment prescribed in the proviso (2) of paragraph 65-2 of the Implementation Guidance on Tax Effect Accounting (ASBJ Guidance No. 28, October 28, 2022; hereinafter referred to as the "Revised Implementation Guidance 2022"). This change in accounting policies has no impact on the quarterly consolidated financial statements.